Trial intelligence / Profile preview

Voriconazole pharmacokinetics and SBECD accumulation in dialysis-dependent intensive care patients

2007-000242-12Phase 3Terminated

Sponsor: Hannover Clinical Trial Center
Start: Aug 2007
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Countries: 1

Overview

Phase 3, open-label trial of voriconazole in invasive mycoses (2 cohorts), sponsored by Hannover Clinical Trial Center. Primary endpoints: Accumulation of SBECD after single and repeated intravenous voriconazole dosing, Single-dose pharmacokinetics of intravenous voriconazole and 1 more. Started Aug 2007; status: terminated.

Drugs

voriconazole

Conditions

invasive mycoses

Beyond the preview

Go deeper on 2007-000242-12.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2007-000242-12.